International Business Development

Recently, Bravo Pharmaceutical Private Ltd, has chosen Kirovograd, Ukraine to implement new direction of medical science and practice telemedicine in 23 hospitals. The company is successfully operating in the pharmaceutical market since few decades, also actively engaged in the development and implementation of IT technologies, such as telemedicine. In this area, the company has established cooperation with Denmark and India in the queue – Ukraine. Presenting the goals and objectives of the project, the company intends to set up inevery region of Ukraine telemedicine centers that work closely with leading capital and foreign hospitals. The first such center should be operational in Kirovograd at one of the Government hospitals. Besides the main purpose, the telemedicine center will provide remote medical aid for patients, the method used for the exchange of invaluable experience in research and scientific developments are training the medical personnel.

UKRAINE Recently, Bravo Pharmaceutical Private Ltd, has chosen Kirovograd, Ukraine to implement new direction of medical science and practice telemedicine in 23 hospitals. The company is successfully operating in the pharmaceutical market since few decades, also actively engaged in the development and implementation of IT technologies, such as telemedicine. In this area, the company has established cooperation with Denmark and India in the queue – Ukraine. Presenting the goals and objectives of the project, the company intends to set up inevery region of Ukraine telemedicine centers that work closely with leading capital and foreign hospitals. The first such center should be operational in Kirovograd at one of the Government hospitals. Besides the main purpose, the telemedicine center will provide remote medical aid for patients, the method used for the exchange of invaluable experience in research and scientific developments are training the medical personnel. Realizing that not all citizens are aware of the new technology in the treatment of its uniqueness, the first step is to extensive outreach, particularly among residents of remote villages, which will focus the first phase of the project. Deputy Head Andrew Nikolaenko expressed interest in working with a foreign company in improving quality of healthcare. The official also said that in Kirovohrad region this year have already started to apply treatment using telemedicine, particularly in the perinatal center.
Recently we have been invited by ministry of Health of Ukraine to Set Up the Telemedicine in Kiev & Kirovograd Ukraine

EXECUTIVE SUMMARY

Diagnosis and treatment of cancer is an ongoing challenge for clinicians and researchers for the past several decades. Most cancers are aggressive and advance quickly before the disease is identified or prognosis is made. A need for early diagnosis and treatment for cancers is growing rapidly. Early detection and diagnosis can define the treatment for patients and better outcomes. Because each tumour is different, it is necessary to identify the biology of individual tumours expressed as biomarkers. Identifying the correct pattern of biomarkers and developing antibodies for early diagnosis is first step in the treatment of cancers. Development of new blood based assays will be a breakthrough in cancer testing. We propose to develop new assays for early detection of Cancers using biomarker discovery approach.

WHAT ARE BIOMARKERS?

According to the National Institute of Health (NIH) of the United States, a biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Biomarkers are found in body fluids and tissue that indicate the risk or presence of cancers before it develops and cause symptoms. Thesebiomarkers are expressed long before the disease has started or progressed. Biomarkers are useful tools in the early diagnosis and for targeted drug therapies. Biomarkers are identified by various methods. We propose to develop pancreatic cancer biomarkers using a mass spectrophotometric approach. Development process Mass Spectrophotometry (MS) of cancer cell lines: MS measures the molecular weight of MS, data-selected proteomes ofa protein; it is the method of will progress to immunoassays for in choice for the detection and situ expression of proteins. Characterization of post – Identifying target biomarkers: translational modifications and peptide mass fingerprinting potentially can identify any mass spectrum data will be covalent modification that alters analyzed. Subsequently,structural the mass of a protein. It is a information of the peptides will be preferred technique for gathered. Finally, individual pieces characterization and quality of information from the spectrum control of recombinant proteins will be identified using ‘precursor and other macromolecules. it is ion fingerprinting’. This will serve as now commonly used for the foundation for developing new characterization of proteomics biomarkers and phospho-proteomics, despite Immunohistochemistry(IHC) for the complexity of its modern early detection components. This technology has after data analysis, correct the advantage of yielding biomarkers (biomarker targets) for information-rich data. Pancreatic cancers will be cancer cell lines will be selected and antobodies will be subjected to MS analysis. Cell developed. Immunohistochemistry lines will be cultured and grown to will be applied for tissue based yield approximately 200mg of immunoassays (immunohistochemis protein. We plan to analyze 12-15 try). Histological expression I human cell lines in the first year overexpression loss of expression using MS technology. After analysis of a large number of will be determined. Biomarkers with significantly elevated levels will be identified for development of assays from bloodserum and/or plasma of patients.

BLOOD BASED ASSAYS FOR EARLY DETECTION OF PANCREATIC CANCERS:

We proposed to develop new assays (ELISA-based) for identified biomarker targets using patient blood that can be used for early detection, prognosis and development of new therapeutic drugs.

BUSINESS PLAN:

We plan to manufacture diagnostic assay kits and make them commercially available for hospitals across the country. It is too early to quote the cost per kit, however based on market research it normally takes 3-5 years before the actual release of any licensed product of a biotech production.

UZBEKISTAN Bravo Pharmaceutical focus on providing high quality appropriately priced products to its customers and supports all these with dedicated customer service. Bravo Pharmaceuticals has a multi cultural, multilingual and multinational workforce of employees in India and CIS. The Company has recently proposed to establish its first 100% owned manufacturing unit at Free Zone Navoi, Uzbekistan. We have proposed the production of fifteen formulations and gradually we will increase the capacity of production from 5 million tablets to 10 million tabs per month. The unit is export oriented unit and in next phase we will export the products to six neighboring countries in CIS. We are focusing on areas- “Ayurvedic”, Herbal and Allopathic Formulations both for Human and Veterinary, Active Pharmaceutical Ingredients, New Drug Discovery, Novel Drug Delivery, Analytical Research, Biotechnology, Plant Tissue Culture, Biosynthesis, Genetic Engineering, Vaccines, Immunoglobuin’s- the entire gamut of a Life Sciences Company. Recently we have signed an agreement with Uzbek State Joint Stock Concern “Uzpharmsanoat” to invest 5.2 Million USD in three years down the line.

Our Facebook Page